热门资讯> 正文
2022-12-31 15:22
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA – Get Rating) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.23 and traded as high as $0.36. Idera Pharmaceuticals shares last traded at $0.35, with a volume of 384,137 shares.
Separately, StockNews.com started coverage on shares of Idera Pharmaceuticals in a research note on Friday, December 23rd. They set a "sell" rating on the stock.
Get Idera Pharmaceuticals alerts:The firm's 50 day simple moving average is $0.25 and its 200-day simple moving average is $0.23. The company has a market cap of $21.82 million, a price-to-earnings ratio of -1.09 and a beta of 1.36.
Idera Pharmaceuticals (NASDAQ:IDRA – Get Rating) last announced its earnings results on Monday, November 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter.An institutional investor recently bought a new position in Idera Pharmaceuticals stock. Millennium Management LLC purchased a new stake in shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA – Get Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 122,238 shares of the biotechnology company's stock, valued at approximately $56,000. Millennium Management LLC owned about 0.23% of Idera Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 12.18% of the company's stock.
(Get Rating)
Idera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.